0001178913-18-002109.txt : 20180723 0001178913-18-002109.hdr.sgml : 20180723 20180723063201 ACCESSION NUMBER: 0001178913-18-002109 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20180723 FILED AS OF DATE: 20180723 DATE AS OF CHANGE: 20180723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRINITY BIOTECH PLC CENTRAL INDEX KEY: 0000888721 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22320 FILM NUMBER: 18963567 BUSINESS ADDRESS: STREET 1: IDA BUSINESS PARK, BRAY, CO WICKLOW STREET 2: IRELAND CITY: DUBLIN IRELAND STATE: L2 ZIP: 18 BUSINESS PHONE: 01135312955111 MAIL ADDRESS: STREET 1: 3 ROCK ROAD STREET 2: SANDYFORD INDUSTRIAL ESTATES CITY: DUBLIN IRELAND STATE: L2 ZIP: 18 6-K 1 zk1821905.htm 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
F O R M  6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2018

TRINITY BIOTECH PLC
(Name of Registrant)

IDA Business Park
Bray, Co. Wicklow
Ireland
 (Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):           

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes ☐          No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                 

   
   
Press Release dated July 19, 2018
  
   
Contact:   Trinity Biotech plc                                 
   Kevin Tansley                    
   (353)-1-2769800                                 
   E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
 
 
Trinity Biotech Announces Results for Q2, 2018
 
DUBLIN, Ireland (July 19, 2018)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2018.

Quarter 2 Results

Total revenues for Q2, 2018 were $25.0m compared to $25.4m in Q2, 2017.
 
   
2017
Quarter 2
    
2018
Quarter 2
    
Increase/
(decrease)
  
   
US$’000
    
US$’000
    
%
  
Point-of-Care
    
4,350
      
4,019
      
(7.6
)%
Clinical Laboratory
    
21,098
      
20,983
      
(0.6
)%
Total
    
25,448
      
25,002
      
(1.8
)%
 
Point-of-Care revenues for Q2, 2018 decreased by $0.3m. This was attributable to lower sales of HIV products in Africa due to the normal fluctuations which characterise that market, in addition to reduced HIV sales in the USA due to continued lower federal government spending in this area.
 
Meanwhile, Clinical Laboratory sales for the quarter were $21.0m versus $21.1m for the corresponding period last year, thus representing a decrease of 0.6%.  This was due to higher diabetes and autoimmunity revenues being offset by lower Lyme revenues as a result of severe winter weather conditions in the north-eastern USA which extended into Spring thus delaying the start of the Lyme season.
 
The gross margin for the quarter was 43.2%, which compares favourably to 42.5% achieved in Q2, 2017 This improvement was partly attributable to cost savings implemented during the quarter.

Research and Development expenses increased marginally from $1.3m in Q2, 2017 to $1.4m for the current quarter, whilst Selling, General and Administrative (SG&A) expenses decreased from $7.6m to $7.4m in the same period. Share option expense for the quarter increased from $0.1m to $0.3m due to an unusually low charge in Q2 of last year and caused total indirect costs to increase from $9.0m to $9.1m.

Operating profit fell slightly from $1.8m to $1.7m due to the increase in indirect costs, which was driven entirely by a higher share option charge this quarter.

Financial income for the quarter remained constant at $0.2m whilst interest payable, mainly arising on the Company’s exchangeable notes, was also static at $1.2m.  Non-cash expenses were immaterial this quarter as the gain of almost $0.2m arising on a decrease in the fair value of the embedded derivatives associated with the exchangeable notes was offset by a non-cash interest charge of $0.2m.

The Company recorded a profit, excluding non-cash items of $0.6m for the quarter, which equates to earnings per share of 2.9 cents compared to 3.1 cents in the equivalent period last year. Fully diluted EPS for the quarter was 6.7 cents compared to 6.8 cents in Q2, 2017.

EBITDA before share option expense for the quarter was $2.9m.

Comments

Commenting on the results, Kevin Tansley, Chief Financial Officer, said “Operating profit fell slightly from $1.8m to $1.7m when compared to the equivalent quarter last year. The impact of lower revenues due to lower Lyme sales was offset by an improvement in gross margin from 42.5% to 43.2%.  However, indirect costs increased from 9.0m to 9.1m, though this increase was entirely driven by an increase in share option expense due an unusually low charge in Q2 of last year.  However, cash based indirect costs actually fell in the quarter.  This was partly driven by cost cutting measures implemented during the quarter, the impact of which will be more greatly felt in subsequent quarters.  Diluted EPS for the quarter was broadly flat at 6.7 cents, whilst year to date EPS was 13.9 cents compared with 11.7 cents for the first six months of 2017.”

Ronan O’Caoimh, CEO of Trinity said “Whilst revenues were down 1.8% compared to Q2 last year our profitability was largely unaffected.  This was largely due to the impact of cost savings measures that we undertook during the quarter. It is of note that most of the measures were implemented midway during the quarter and hence we will not see their full impact until next quarter. In the months ahead we will continue to seek further cost savings. These measures are being driven by our objective to reach a cash flow neutral position for the company for the financial year 2019. ”

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
 
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
 

Trinity Biotech plc
Consolidated Income Statements

(US$000’s  except share data)
 
 
  
Three Months Ended
June 30,
2018
(unaudited)
    
Three Months Ended
June 30,
2017
(unaudited)
    
Six Months
Ended
June 30,
2018
(unaudited)
    
Six Months
Ended
June 30,
2017
(unaudited)
  
                         
Revenues
    
25,002
      
25,448
      
48,801
      
48,984
  
                                 
Cost of sales
    
(14,194
)
    
(14,629
)
    
(27,565
)
    
(28,274
)
                                 
Gross profit
    
10,808
      
10,819
      
21,236
      
20,710
  
Gross margin %
    
43.2
%
    
42.5
%
    
43.5
%
    
42.3
%
                                 
Other operating income
    
24
      
26
      
48
      
49
  
                                 
Research & development expenses
    
(1,419
)
    
(1,322
)
    
(2,691
)
    
(2,651
)
Selling, general and administrative expenses
    
(7,358
)
    
(7,561
)
    
(14,298
)
    
(14,588
)
Indirect share based payments
    
(329
)
    
(130
)
    
(763
)
    
(380
)
                                 
Operating profit
    
1,726
      
1,832
      
3,532
      
3,140
  
                                 
Financial income
    
196
      
196
      
401
      
373
  
Financial expenses
    
(1,158
)
    
(1,169
)
    
(2,317
)
    
(2,339
)
Net financing expense
    
(962
)
    
(973
)
    
(1,916
)
    
(1,966
)
                                 
Profit before tax & non-cash items
    
764
      
859
      
1,616
      
1,174
  
                                 
Income tax expense
    
(158
)
    
(176
)
    
(290
)
    
(275
)
                                 
Profit after tax before non-cash items     606       683      
1,326
       899  
                                 
Non-cash financial (expense) / income
    
(12
)
    
219
      
(354
)
    
1,249
  
                                 
Profit after tax and non-cash items
    
594
      
902
      
972
      
2,148
  
                                 
Earnings per ADR (US cents)
    
2.8
      
4.1
      
4.7
      
9.8
  
                                 
Earnings per ADR excluding non-cash financial (expense) / income (US cents)
    
2.9
      
3.1
      
6.3
      
4.1
  
                                 
Diluted earnings per ADR (US cents)*
    
6.7
      
6.8
      
13.9
      
11.7
  
                                 
Weighted average no. of ADRs used in computing basic earnings per ADR
    
20,901,703
      
21,847,528
      
20,904,777
      
21,974,369
  
                                 
Weighted average no. of ADRs used in computing diluted earnings per ADR
    
26,157,644
      
27,104,994
      
26,166,077
      
27,231,931
  

* Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. In a reporting period where it is anti-dilutive, diluted earnings per ADR should be constrained to equal basic earnings per ADR.

 The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

Trinity Biotech plc
Consolidated Balance Sheets

   
June 30,
2018
US$ ‘000
(unaudited)
    
Mar 31,
2018
US$ ‘000
(unaudited)
    
Dec 31,
2017
US$ ‘000
(unaudited)
  
ASSETS
                  
Non-current assets
                  
Property, plant and equipment
    
7,769
      
7,033
      
5,800
  
Goodwill and intangible assets
    
68,263
      
66,474
      
64,754
  
Deferred tax assets
    
9,047
      
8,968
      
8,698
  
Other assets
    
701
      
779
      
771
  
Total non-current assets
    
85,780
      
83,254
      
80,023
  
                         
Current assets
                        
Inventories
    
34,818
      
34,179
      
32,805
  
Trade and other receivables
    
23,138
      
22,118
      
20,740
  
Income tax receivable
    
1,287
      
1,234
      
1,440
  
Cash and cash equivalents
    
49,426
      
53,895
      
57,607
  
Total current assets
    
108,669
      
111,426
      
112,592
  
                         
TOTAL ASSETS
    
194,449
      
194,680
      
192,615
  
                         
EQUITY AND LIABILITIES
                        
Equity attributable to the equity holders of the parent
                        
Share capital
    
1,224
      
1,224
      
1,224
  
Share premium
    
16,187
      
16,187
      
16,187
  
Accumulated surplus
    
47,430
      
46,837
      
46,157
  
Other reserves
    
1,853
      
1,529
      
1,628
  
Total equity
    
66,694
      
65,777
      
65,196
  
                         
Current liabilities
                        
Income tax payable
    
252
      
344
      
310
  
Trade and other payables
    
20,494
      
21,761
      
20,870
  
Provisions
    
50
      
50
      
50
  
Total current liabilities
    
20,796
      
22,155
      
21,230
  
                         
Non-current liabilities
                        
Exchangeable senior note payable
    
95,179
      
95,167
      
94,825
  
Other payables
    
341
      
453
      
532
  
Deferred tax liabilities
    
11,439
      
11,128
      
10,832
  
Total non-current liabilities
    
106,959
      
106,748
      
106,189
  
                         
TOTAL LIABILITIES
    
127,755
      
128,903
      
127,419
  
                         
TOTAL EQUITY AND LIABILITIES
    
194,449
      
194,680
      
192,615
  
 
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).


Trinity Biotech plc
Consolidated Statement of Cash Flows

(US$000’s)
  
Three Months
Ended
June 30,
2018
(unaudited)
    
Three Months
Ended
June 30,
2017
(unaudited)
    
Six Months
Ended
June 30,
2018
(unaudited)
    
Six Months
Ended
June 30,
2017
(unaudited)
  
                         
Cash and cash equivalents at beginning of period
    
53,895
      
69,851
      
57,607
      
77,108
  
                                 
Operating cash flows before changes in working capital
    
3,204
      
3,739
      
6,462
      
6,006
  
Changes in working capital
    
(1,466
)
    
(367
)
    
(4,145
)
    
(2,575
)
Cash generated from operations
    
1,738
      
3,372
      
2,317
      
3,431
  
                                 
Net Interest and Income taxes (paid)/received
    
(30
)
    
62
      
175
      
239
  
                                 
Capital Expenditure & Financing (net)
    
(3,877
)
    
(3,185
)
    
(7,939
)
    
(6,832
)
                                 
Free cash flow
    
(2,169
)
    
249
      
(5,447
)
    
(3,162
)
                                 
Share buyback
    
-
      
(3,096
)
    
(434
)
    
(4,929
)
                                 
Payment of HIV-2 licence fee
    
-
      
-
      
-
      
(1,112
)
                                 
30 year Exchangeable Note interest payment
    
(2,300
)
    
(2,300
)
    
(2,300
)
    
(2,300
)
                                 
Once-off items
    
-
      
(727
)
    
-
      
(1,628
)
                                 
Cash and cash equivalents at end of period
    
49,426
      
63,977
      
49,426
      
63,977
  
 
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
TRINITY BIOTECH PLC
         (Registrant)
  
       
By:
/s/ Kevin Tansley  
    Kevin Tansley  
    Chief Financial Officer  
       
Date:  19 July 2018



 EX-101.INS 2 trib-20180630.xml XBRL INSTANCE DOCUMENT 0000888721 2018-01-01 2018-06-30 0000888721 2017-01-01 2017-06-30 0000888721 2018-04-01 2018-06-30 0000888721 2017-04-01 2017-06-30 0000888721 2018-06-30 0000888721 2018-03-31 0000888721 2017-12-31 0000888721 2017-03-31 0000888721 2017-06-30 0000888721 2016-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure TRINITY BIOTECH PLC 0000888721 6-K 2018-06-30 false --12-31 Q2 2018 -1916000 -1966000 -962000 -973000 2317000 2339000 1158000 1169000 401000 373000 196000 196000 3532000 3140000 1726000 1832000 14298000 14588000 7358000 7561000 2691000 2651000 1419000 1322000 48000 49000 24000 26000 21236000 20710000 10808000 10819000 27565000 28274000 14194000 14629000 48801000 48984000 25002000 25448000 194449000 194680000 192615000 127755000 128903000 127419000 106959000 106748000 106189000 11439000 11128000 10832000 20796000 22155000 21230000 50000 50000 50000 20494000 21761000 20870000 252000 344000 310000 66694000 65777000 65196000 1853000 1529000 1628000 47430000 46837000 46157000 16187000 16187000 16187000 1224000 1224000 1224000 194449000 194680000 192615000 108669000 111426000 112592000 49426000 53895000 57607000 69851000 63977000 77108000 1287000 1234000 1440000 23138000 22118000 20740000 34818000 34179000 32805000 85780000 83254000 80023000 701000 779000 771000 9047000 8968000 8698000 68263000 66474000 64754000 7769000 7033000 5800000 341000 453000 532000 95179000 95167000 94825000 0.435 0.423 0.432 0.425 1616000 1174000 764000 859000 1326000 899000 606000 683000 972000 2148000 594000 902000 -354000 1249000 -12000 219000 4.7 9.8 2.8 4.1 13.9 11.7 6.7 6.8 6.3 4.1 2.9 3.1 20904777 21974369 20901703 21847528 26166077 27231931 26157644 27104994 -4145000 -2575000 -1466000 -367000 6462000 6006000 3204000 3739000 2317000 3431000 1738000 3372000 175000 239000 -30000 62000 -7939000 -6832000 -3877000 -3185000 -5447000 -3162000 -2169000 249000 -434000 -4929000 -3096000 -1112000 -2300000 -2300000 -2300000 -2300000 -1628000 -727000 763000 380000 329000 130000 290000 275000 158000 176000 Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. In a reporting period where it is anti-dilutive, diluted earnings per ADR should be constrained to equal basic earnings per ADR. EX-101.SCH 3 trib-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Income Statements link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 trib-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 5 trib-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 trib-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Profit or loss [abstract] Revenues Cost of sales Gross profit Gross margin % Other operating income Research & development expenses Selling, general and administrative expenses Indirect share based payments Operating profit Financial income Financial expenses Net financing expense Profit before tax & non-cash items Income tax expense Profit after tax before non-cash items Non-cash financial (expense) / income Profit after tax and non-cash items Earnings per ADR (US cents) Earnings per ADR excluding non-cash financial (expense) / income (US cents) Diluted earnings per ADR (US cents) Weighted average no. of ADRs used in computing basic earnings per ADR Weighted average no. of ADRs used in computing diluted earnings per ADR Statement of financial position [abstract] Assets Non-current assets Property, plant and equipment Goodwill and intangible assets Deferred tax assets Other assets Total non-current assets Current assets Inventories Trade and other receivables Income tax receivable Cash and cash equivalents Total current assets TOTAL ASSETS EQUITY AND LIABILITIES Equity attributable to the equity holders of the parent Share capital Share premium Accumulated surplus Other reserves Total equity Current liabilities Income tax payable Trade and other payables Provisions Total current liabilities Non-current liabilities Exchangeable senior note payable Other payables Deferred tax liabilities Total non-current liabilities TOTAL LIABILITIES TOTAL EQUITY AND LIABILITIES Statement of cash flows [abstract] Cash and cash equivalents at beginning of period Operating cash flows before changes in working capital Changes in working capital Cash generated from operations Net Interest and Income taxes (paid)/received Capital Expenditure & Financing (net) Free cash flow Share buyback Payment of licence fee Exchangeable Note interest payment Once-off items Cash and cash equivalents at end of period Net financing (expense)/income. Exchangeable senior note payable. Percentage of gross margin. Profit after tax before non-cash items. Non-cash financial (expense) / income. Earnings per excluding non-cash financial (expense) / income. Share buyback. Payment of licence fee. Once-off items. Cost of sales Gross profit Research and development expense Selling, general and administrative expense Adjustments for share-based payments Profit (loss) from operating activities Finance costs NetFinancingExpenseIncome Tax expense (income), continuing operations ProfitLossAfterTax Profit (loss) Non-current assets [Default Label] Current assets [Default Label] Assets [Default Label] Equity Current liabilities [Default Label] Non-current liabilities [Default Label] Liabilities Equity and liabilities EX-101.PRE 7 trib-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 image00001.jpg begin 644 image00001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information
 6 Months Ended
Jun. 30, 2018
Document And Entity Information  
Entity Registrant Name TRINITY BIOTECH PLC
Entity Central Index Key 0000888721
Document Type 6-K
Document Period End Date Jun. 30, 2018
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Fiscal Period Focus Q2
Document Fiscal Year Focus 2018
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Income Statements - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Profit or loss [abstract]        
Revenues $ 25,002 $ 25,448 $ 48,801 $ 48,984
Cost of sales (14,194) (14,629) (27,565) (28,274)
Gross profit $ 10,808 $ 10,819 $ 21,236 $ 20,710
Gross margin % 43.20% 42.50% 43.50% 42.30%
Other operating income $ 24 $ 26 $ 48 $ 49
Research & development expenses (1,419) (1,322) (2,691) (2,651)
Selling, general and administrative expenses (7,358) (7,561) (14,298) (14,588)
Indirect share based payments (329) (130) (763) (380)
Operating profit 1,726 1,832 3,532 3,140
Financial income 196 196 401 373
Financial expenses (1,158) (1,169) (2,317) (2,339)
Net financing expense (962) (973) (1,916) (1,966)
Profit before tax & non-cash items 764 859 1,616 1,174
Income tax expense (158) (176) (290) (275)
Profit after tax before non-cash items 606 683 1,326 899
Non-cash financial (expense) / income (12) 219 (354) 1,249
Profit after tax and non-cash items $ 594 $ 902 $ 972 $ 2,148
Earnings per ADR (US cents) $ 2.8 $ 4.1 $ 4.7 $ 9.8
Earnings per ADR excluding non-cash financial (expense) / income (US cents) 2.9 3.1 6.3 4.1
Diluted earnings per ADR (US cents) [1] $ 6.7 $ 6.8 $ 13.9 $ 11.7
Weighted average no. of ADRs used in computing basic earnings per ADR 20,901,703 21,847,528 20,904,777 21,974,369
Weighted average no. of ADRs used in computing diluted earnings per ADR 26,157,644 27,104,994 26,166,077 27,231,931
[1] Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. In a reporting period where it is anti-dilutive, diluted earnings per ADR should be constrained to equal basic earnings per ADR.
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Non-current assets      
Property, plant and equipment $ 7,769 $ 7,033 $ 5,800
Goodwill and intangible assets 68,263 66,474 64,754
Deferred tax assets 9,047 8,968 8,698
Other assets 701 779 771
Total non-current assets 85,780 83,254 80,023
Current assets      
Inventories 34,818 34,179 32,805
Trade and other receivables 23,138 22,118 20,740
Income tax receivable 1,287 1,234 1,440
Cash and cash equivalents 49,426 53,895 57,607
Total current assets 108,669 111,426 112,592
TOTAL ASSETS 194,449 194,680 192,615
Equity attributable to the equity holders of the parent      
Share capital 1,224 1,224 1,224
Share premium 16,187 16,187 16,187
Accumulated surplus 47,430 46,837 46,157
Other reserves 1,853 1,529 1,628
Total equity 66,694 65,777 65,196
Current liabilities      
Income tax payable 252 344 310
Trade and other payables 20,494 21,761 20,870
Provisions 50 50 50
Total current liabilities 20,796 22,155 21,230
Non-current liabilities      
Exchangeable senior note payable 95,179 95,167 94,825
Other payables 341 453 532
Deferred tax liabilities 11,439 11,128 10,832
Total non-current liabilities 106,959 106,748 106,189
TOTAL LIABILITIES 127,755 128,903 127,419
TOTAL EQUITY AND LIABILITIES $ 194,449 $ 194,680 $ 192,615
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Statement of cash flows [abstract]        
Cash and cash equivalents at beginning of period $ 53,895 $ 69,851 $ 57,607 $ 77,108
Operating cash flows before changes in working capital 3,204 3,739 6,462 6,006
Changes in working capital (1,466) (367) (4,145) (2,575)
Cash generated from operations 1,738 3,372 2,317 3,431
Net Interest and Income taxes (paid)/received (30) 62 175 239
Capital Expenditure & Financing (net) (3,877) (3,185) (7,939) (6,832)
Free cash flow (2,169) 249 (5,447) (3,162)
Share buyback (3,096) (434) (4,929)
Payment of licence fee (1,112)
Exchangeable Note interest payment (2,300) (2,300) (2,300) (2,300)
Once-off items (727) (1,628)
Cash and cash equivalents at end of period $ 49,426 $ 63,977 $ 49,426 $ 63,977
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 10 66 1 true 0 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://trinitybiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Income Statements Sheet http://trinitybiotech.com/role/IncomeStatements Consolidated Income Statements Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets Sheet http://trinitybiotech.com/role/BalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statement of Cash Flows Sheet http://trinitybiotech.com/role/StatementOfCashFlows Consolidated Statement of Cash Flows Statements 4 false false All Reports Book All Reports trib-20180630.xml trib-20180630.xsd trib-20180630_cal.xml trib-20180630_def.xml trib-20180630_lab.xml trib-20180630_pre.xml http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 19 0001178913-18-002109-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-18-002109-xbrl.zip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